Related Experiment Video

Updated: Aug 17, 2026

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

Satoshi Nagata1, Tomoko Ise, Masanori Onda

  • 1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

Proceedings of the National Academy of Sciences of the United States of America
|May 21, 2005
PubMed

Insights

Researchers identified two membrane-specific epitopes (Ep2 and Ep7) on CD30, crucial for targeting lymphomas. These epitopes avoid competition from soluble CD30, offering a promising strategy for more effective CD30 immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • CD30 is a key target in Hodgkin's lymphoma and anaplastic large cell lymphoma immunotherapy.
  • Soluble CD30 (sCD30) can interfere with CD30-targeting therapies through competitive binding.
  • Identifying CD30 epitopes specific to the cell membrane is crucial for overcoming sCD30-mediated resistance.

Purpose of the Study:

  • To identify and characterize novel epitopes on membrane-associated CD30 that are absent on soluble CD30.
  • To evaluate the potential of these membrane-specific epitopes as superior targets for CD30-directed immunotherapy.
  • To investigate the binding characteristics of anti-CD30 monoclonal antibodies (mAbs) to both membrane and soluble forms of CD30.

Main Methods:

  • Characterization of 27 anti-native CD30 monoclonal antibodies (mAbs) against 8 topographical epitopes.
  • Preparation of soluble CD30 from cell culture supernatants.
  • Enzyme-linked immunosorbent assay (ELISA) and size-exclusion chromatography to assess mAb cross-reactivity and binding to membrane-associated vs. soluble CD30.

Main Results:

  • Two epitopes, Ep2 (amino acids 107-153) and Ep7 (amino acids 282-338), demonstrated minimal cross-reactivity (<2%) with soluble CD30.
  • These Ep2 and Ep7 specific mAbs effectively bound to cell-associated CD30 even in the presence of excess soluble CD30.
  • Membrane-specific mAbs did not form immune complexes with soluble CD30 in mouse serum, unlike mAbs targeting other epitopes.

Conclusions:

  • Ep2 and Ep7 represent membrane-specific epitopes on CD30, unaffected by soluble CD30 interference.
  • These findings suggest that targeting membrane-specific epitopes could enhance the efficacy of CD30-based immunotherapies.
  • The strategy of identifying membrane-specific epitopes may be applicable to other immunotherapy targets.

More Related Videos

Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...